Fan F, Bellister S, Lu J, Ye X, Boulbes D R, Tozzi F, Sceusi E, Kopetz S, Tian F, Xia L, Zhou Y, Bhattacharya R, Ellis L M
Department of Surgical Oncology, Unit 1484, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77230-1402, USA.
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Br J Cancer. 2015 Feb 3;112(3):539-46. doi: 10.1038/bjc.2014.620. Epub 2014 Dec 23.
Isolation of colorectal cancer (CRC) cell populations enriched for cancer stem cells (CSCs) may facilitate target identification. There is no consensus regarding the best methods for isolating CRC stem cells (CRC-SCs). We determined the suitability of various cellular models and various stem cell markers for the isolation of CRC-SCs.
Established human CRC cell lines, established CRC cell lines passaged through mice, patient-derived xenograft (PDX)-derived cells, early passage/newly established cell lines, and cells directly from clinical specimens were studied. Cells were FAC-sorted for the CRC-SC markers CD44, CD133, and aldehyde dehydrogenase (ALDH). Sphere formation and in vivo tumorigenicity studies were used to validate CRC-SC enrichment.
None of the markers studied in established cell lines, grown either in vitro or in vivo, consistently enriched for CRC-SCs. In the three other cellular models, CD44 and CD133 did not reliably enrich for stemness. In contrast, freshly isolated PDX-derived cells or early passage/newly established CRC cell lines with high ALDH activity formed spheres in vitro and enhanced tumorigenicity in vivo, whereas cells with low ALDH activity did not.
PDX-derived cells, early passages/newly established CRC cell lines and cells from clinical specimen with high ALDH activity can be used to identify CRC-SC-enriched populations. Established CRC cell lines should not be used to isolate CSCs.
分离富含癌干细胞(CSCs)的结直肠癌(CRC)细胞群体可能有助于靶点识别。关于分离CRC干细胞(CRC-SCs)的最佳方法尚无共识。我们确定了各种细胞模型和各种干细胞标志物用于分离CRC-SCs的适用性。
研究了已建立的人CRC细胞系、经小鼠传代的已建立的CRC细胞系、患者来源异种移植(PDX)衍生的细胞、早期传代/新建立的细胞系以及直接来自临床标本的细胞。通过荧光激活细胞分选(FAC)对CRC-SC标志物CD44、CD133和醛脱氢酶(ALDH)进行分选。采用成球和体内致瘤性研究来验证CRC-SC的富集情况。
在体外或体内培养的已建立细胞系中研究的标志物,均未始终如一地富集CRC-SCs。在其他三种细胞模型中,CD44和CD133不能可靠地富集干性。相比之下,新鲜分离的PDX衍生细胞或具有高ALDH活性的早期传代/新建立的CRC细胞系在体外形成球体并在体内增强致瘤性,而具有低ALDH活性的细胞则不能。
PDX衍生细胞、早期传代/新建立的CRC细胞系以及来自临床标本且具有高ALDH活性的细胞可用于鉴定富含CRC-SC的群体。已建立的CRC细胞系不应被用于分离CSCs。